Skip to content

Effects of Xanthophylls on Optical Density

Alteration of Optical Density and Plasma Xanthophylls After Short Term Supplementation With Macular Carotenoids in Patients With AMD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01316198
Enrollment
20
Registered
2011-03-16
Start date
2010-06-30
Completion date
2011-07-31
Last updated
2012-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Keywords

human study, AMD, lutein, zeaxanthin, optical density

Brief summary

The objective of the study was to investigate the influence of a intervention with lutein und zeaxanthin from crucifers on the optical density of the macular pigment of patients with non exudative age-related maculopathy. It is hypothesized that the applied study beverage elevates plasma concentrations of the administered xanthophylls and the optical density after 4 weeks of intervention.

Interventions

DIETARY_SUPPLEMENTVerum

10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day

DIETARY_SUPPLEMENTPlacebo

10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin

Sponsors

University of Jena
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patients with non exudative age-related maculopathy

Exclusion criteria

* intake of dietary supplements containing lutein and zeaxanthin

Design outcomes

Primary

MeasureTime frame
Optical density of macular pigment in AMD patients10 weeks

Secondary

MeasureTime frame
Concentration of xanthophylls in plasma of AMD patients10 weeks
blood lipids10 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026